Drug Profile
Research programme: anticancer peptide conjugates - Xigen
Alternative Names: Anticancer peptide conjugates - Xigen; Cytotoxic intracellular peptide conjugates - Xigen; XG-311; XG-311 sq; XG-412; XG-414Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Xigen
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Switzerland (Injection)